Azra Raza

Title: Azra Raza: Innovator in Cancer Research

Introduction

Azra Raza is a prominent inventor based in New York, NY, known for her significant contributions to cancer research. With a focus on myeloid malignancies, she has developed innovative methods and compositions that aim to improve patient outcomes.

Latest Patents

Raza holds two notable patents. The first patent, titled "Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies," relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, particularly myelodysplastic syndromes. This invention aims to identify patients at risk for poor survival outcomes who would benefit from aggressive treatment by characterizing their TED profile using protein and gene expression markers. The second patent, "Methods and compositions for treatment of cancer," discloses a method of treating cancer that is refractory to an anticancer agent. This method involves administering a pharmaceutical composition comprising specific compounds along with an anticancer agent.

Career Highlights

Throughout her career, Azra Raza has worked with esteemed institutions, including Columbia University and Onconova Therapeutics, Inc. Her research has focused on advancing the understanding and treatment of cancer, particularly in the context of myelodysplastic syndromes.

Collaborations

Raza has collaborated with notable individuals in her field, including Abdullah Mahmood Ali and Naomi Galili, who have contributed to her research endeavors.

Conclusion

Azra Raza's innovative work in cancer research has the potential to significantly impact patient care and treatment strategies. Her patents reflect her commitment to advancing medical science and improving outcomes for patients with myeloid malignancies.